Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.
Lorazepam is FDA-approved for the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxiety-associated insomnia. It is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedation/amnesia and for the treatment of status epilepticus.
Some off-label indications of lorazepam include rapid tranquilization of an agitated patient, alcohol withdrawal delirium, alcohol withdrawal syndrome, muscle spasms, insomnia, panic disorder, delirium, chemotherapy-associated anticipatory nausea and vomiting, and psychogenic catatonia.
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Assistance Publique Hopitaux de Marseille, Marseille, France
University of Minnesota, Minneapolis, Minnesota, United States
Covance-Evansville, Evansville, Indiana, United States
Département d'Anesthésie - Réanimation - SMUR - Hôpital Lariboisière, Paris, France
Department of Neurology, Emam Hossein Hospital, Tehran, Nezam Abad, Iran, Islamic Republic of
Shands at the University of Florida, Gainesville, Florida, United States
NYSPI, New York, New York, United States
Mayo Clinic, Scottsdale, Arizona, United States
Chaim Sheba Medical Center, Tel Hashomer, Israel
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.